edotreotide has been researched along with Pancreatic Neoplasms in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 8 (28.57) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 6 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Chiche, L; Debordeaux, F; Marichez, A; Passand, GT; Pinaquy, JB | 1 |
| Champion, L; Cros, J; Hescot, S; Richard, C; Seban, RD | 1 |
| Andreasi, V; Baldassi, F; Bezzi, C; Canevari, C; De Cobelli, F; Falconi, M; Ghezzo, S; Gianolli, L; Magnani, P; Mapelli, P; Muffatti, F; Partelli, S; Picchio, M; Schiavo Lena, M | 1 |
| Fabritius, MP; Mansour, N; Rangan, K; Rübenthaler, J; Tiling, R | 1 |
| Baum, RP; Kulkarni, HR; Singh, A; Zhang, J | 1 |
| Bombardieri, E; Bonacina, M; Ghirardelli, P; Setti, L; Vavassori, V | 1 |
| Bartolomei, M; Bertani, E; Crippa, S; Doglioni, C; Falconi, M; Fazio, N; Grana, CM; Muffatti, F; Partelli, S; Perali, C; Schiavo Lena, M; Zamboni, G | 1 |
| Cacciari, G; Campana, D; Capurso, G; Delle Fave, G; Falconi, M; Nori, F; Panzuto, F; Partelli, S; Tamburrino, D; Tomassetti, P | 1 |
| Hamasaki, A; Harashima, S; Inagaki, N; Nakamoto, Y; Shibue, K | 1 |
| Davi', MV; Francia, G; Salgarello, M | 1 |
| Asti, M; Azzolini, F; Camellini, L; Carlinfante, G; Frasoldati, A; Fraternali, A; Gallo, C; Giunta, FP; Grassi, E; Iori, V; Nicoli, F; Salvo, D; Sassatelli, R; Versari, A | 1 |
| Hartmann, H; Luboldt, HJ; Luboldt, W; Wiedemann, B; Zöphel, K | 1 |
| Choyke, PL; Giesel, FL; Haberkorn, U; Haufe, S; Isermann, B; Kauczor, HU; Kratochwil, C; López-Benítez, R; Mier, W | 1 |
| Bertagna, F; Bettinsoli, G; Biasiotto, G; Bosio, G; Dognini, L; Ferrari, C; Ferrari, V; Franco, F; Giubbini, R; Migliorati, E; Minari, C; Rodella, C; Savelli, G; Tomassetti, P; Zaniboni, A | 1 |
| Castaldi, P; Giordano, A; Rindi, G; Rufini, V; Treglia, G | 1 |
| Bolstad, N; Distante, S; Edwin, B; Johnsrud, K; Kazaryan, AM; Nustad, K; Revheim, ME; Warren, DJ | 1 |
| Antoch, G; Binse, I; Bockisch, A; Boy, C; Brandau, W; Lahner, H; Petersenn, S; Poeppel, TD; Schott, M | 1 |
| Bernard, BF; De Jong, M; Ginj, M; Krenning, E; Mäcke, HR; Reubi, JC; Schmitt, JS; Wenger, S; Wild, D | 1 |
| Dimitrakopoulou-Strauss, A; Eisenhut, M; Haberkorn, U; Henze, M; Mäcke, HR; Schuhmacher, J; Strauss, LG | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Kahn, D; Karwal, M; Madsen, M; Menda, Y; Miller, S; O'Dorisio, S; O'Dorisio, T; Ponto, J; Squires, S; Walkner, W | 1 |
| Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Valkema, R | 1 |
| Barone, R; Borson-Chazot, F; Chauvin, F; Gogou, L; Jamar, F; Krenning, EP; Kvols, LK; Pauwels, S; Valkema, R; Walrand, S | 1 |
| Chen, CH; Hen, SL; Ho, YJ; Hsia, CC; Hung, GU; Lin, WY; Lin, YC; Luo, TY | 1 |
| Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F | 1 |
| Albert, R; Bruns, C; Raulf, F; Smith-Jones, PM; Stolz, B; Weckbecker, G | 1 |
| Chinol, M; Cremonesi, M; Mäcke, HR; Paganelli, G; Zoboli, S | 1 |
| Finn, RD; Guenther, I; Kothari, PJ; Larson, SM; Maecke, HR; Ruan, S; Ugur, O; Zanzonico, P | 1 |
1 review(s) available for edotreotide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
Topics: Algorithms; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, Somatostatin; Sensitivity and Specificity; Thoracic Neoplasms; Tomography, X-Ray Computed | 2012 |
6 trial(s) available for edotreotide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
Topics: Adult; Aged; Chromogranin A; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Radionuclide Imaging; Retreatment; Survival Rate; Yttrium Radioisotopes | 2012 |
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Topics: Adult; Aged; Algorithms; Body Burden; Dose-Response Relationship, Radiation; Female; Gastrointestinal Neoplasms; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Pancreatic Neoplasms; Radiation Injuries; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Relative Biological Effectiveness; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Treatment Outcome | 2005 |
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Topics: Adult; Aged; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Yttrium Radioisotopes | 1999 |
21 other study(ies) available for edotreotide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Serous cystadenoma mimicking cystic pancreatic neuroendocrine tumor on
Topics: Cystadenoma, Serous; Gallium Radioisotopes; Humans; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
68 Ga-DOTATOC PET/CT Imaging of a Muscular Solitary Fibrous Tumor.
Topics: Aged; Female; Hemangiopericytoma; Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Receptors, Somatostatin; Solitary Fibrous Tumors | 2023 |
Somatostatin receptor activity assessed by
Topics: Adaptor Proteins, Signal Transducing; Co-Repressor Proteins; Gallium Radioisotopes; Humans; Molecular Chaperones; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, Somatostatin; Retrospective Studies; X-linked Nuclear Protein | 2023 |
68 Ga-DOTATOC PET/CT in Pancreatic Metastasis From Clear Cell Renal Cell Carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2023 |
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist.
Topics: Adult; Female; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals | 2020 |
Topics: Adenocarcinoma; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Octreotide; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms | 2022 |
Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
Topics: Aged; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Octreotide; Pancreatectomy; Pancreatic Neoplasms; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
Topics: Aged; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2013 |
[Case report; a case of gastorinoma with subclinical insulinoma presenting repeated episodes of hypoglycemic attack].
Topics: Adult; Humans; Hypoglycemia; Insulin; Insulinoma; Male; Octreotide; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Positive (68)Ga-DOTATOC-PET/CT after cortisol level control during ketoconazole treatment in a patient with liver metastases from a pancreatic neuroendocrine tumor and ectopic Cushing syndrome.
Topics: Cushing Syndrome; Gallium Radioisotopes; Humans; Hydrocortisone; Ketoconazole; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Duodenal Neoplasms; Endosonography; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2010 |
Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, Somatostatin; Reference Standards; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
A man with abdominal pain: enough evidence for surgery?
Topics: Abdominal Pain; Adrenocorticotropic Hormone; Antibodies, Heterophile; Artifacts; Diagnosis, Differential; False Positive Reactions; Gallium Radioisotopes; Humans; Hyperpigmentation; Immunoassay; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pancreatitis; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Water-Electrolyte Imbalance | 2012 |
Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Topics: Aged; Aged, 80 and over; Female; Gallium Radioisotopes; Gastrointestinal Neoplasms; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
SNM 2012 image of the year.
Topics: Bismuth; Humans; Intestinal Neoplasms; Liver; Neuroendocrine Tumors; Nuclear Medicine; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Societies, Scientific; Stomach Neoplasms; Treatment Failure | 2012 |
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Drug Evaluation, Preclinical; Isotope Labeling; Ligands; Male; Metabolic Clearance Rate; Metals; Octreotide; Organ Specificity; Organometallic Compounds; Pancreatic Neoplasms; Protein Binding; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Tissue Distribution | 2003 |
Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
Topics: Gallium Radioisotopes; Humans; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin | 2004 |
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Humans; Lutetium; Male; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Somatostatin; Survival Analysis; Treatment Outcome; Yttrium | 2005 |
A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors.
Topics: Animals; Indium Radioisotopes; Male; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Tissue Distribution | 2006 |
The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.
Topics: Animals; Humans; Octreotide; Pancreatic Neoplasms; Polymerase Chain Reaction; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Tissue Distribution; Yttrium Radioisotopes | 1998 |
Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
Topics: Animals; Chromatography, High Pressure Liquid; Gallium Radioisotopes; In Vitro Techniques; Mice; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Receptors, Somatostatin; Tumor Cells, Cultured | 2002 |